Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares IssuedShort-Term Debt issuances
Growth Metrics
Income Statement
Others
Ratios

Cannabis Bioscience International Holdings (CBIH) Change in Accured Expenses (2023 - 2026)

Cannabis Bioscience International Holdings' Change in Accured Expenses history spans 4 years, with the latest figure at -$25993.0 for Q1 2026.

  • On a quarterly basis, Change in Accured Expenses fell 274.71% to -$25993.0 in Q1 2026 year-over-year; TTM through Feb 2026 was $39699.0, a 151.87% increase, with the full-year FY2025 number at -$65515.0, down 177.27% from a year prior.
  • Change in Accured Expenses hit -$25993.0 in Q1 2026 for Cannabis Bioscience International Holdings, down from $116116.0 in the prior quarter.
  • Over the last five years, Change in Accured Expenses for CBIH hit a ceiling of $116116.0 in Q4 2025 and a floor of -$61439.0 in Q2 2024.
  • Historically, Change in Accured Expenses has averaged $14258.2 across 4 years, with a median of $23023.0 in 2023.
  • Biggest five-year swings in Change in Accured Expenses: crashed 351.59% in 2024 and later soared 487.45% in 2025.
  • Tracing CBIH's Change in Accured Expenses over 4 years: stood at $43566.0 in 2023, then crashed by 168.79% to -$29969.0 in 2024, then soared by 487.45% to $116116.0 in 2025, then crashed by 122.39% to -$25993.0 in 2026.
  • Business Quant data shows Change in Accured Expenses for CBIH at -$25993.0 in Q1 2026, $116116.0 in Q4 2025, and -$50424.0 in Q2 2025.